Cep290 targeting antisense oligonucleotide (Stoke Therapeutics)

N/A

Report date: 2025/01/26 18:02:50
NME

Base Information

Drug NameCep290 targeting antisense oligonucleotide (Stoke Therapeutics)
Drug Alias NameCep290 gene stimulator (Stoke Therapeutics)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionCentrosomal protein of 290 kDa stimulants
TargetsCentrosomal protein of 290 kDa
Therapy Area/IndicationsEye Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStoke Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesStoke Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsEye Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A